Equities

Astrazeneca Pharma India Ltd

ASTRAZEN:NSI

Astrazeneca Pharma India Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)6,319.85
  • Today's Change39.35 / 0.63%
  • Shares traded11.76k
  • 1 Year change+35.88%
  • Beta0.4967
Data delayed at least 15 minutes, as of Nov 22 2024 10:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Astrazeneca Pharma India Ltd grew revenues 29.17% from 10.03bn to 12.96bn while net income improved 62.66% from 992.90m to 1.62bn.
Gross margin44.88%
Net profit margin5.52%
Operating margin5.17%
Return on assets6.99%
Return on equity12.28%
Return on investment11.44%
More ▼

Cash flow in INRView more

In 2024, Astrazeneca Pharma India Ltd did not generate a significant amount of cash. However, the company earned 278.70m from its operations for a Cash Flow Margin of 2.15%. In addition the company generated 217.40m cash from investing, though they paid out 443.80m more in financing than they received.
Cash flow per share41.06
Price/Cash flow per share153.62
Book value per share271.74
Tangible book value per share270.98
More ▼

Balance sheet in INRView more

Astrazeneca Pharma India Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio2.25
Quick ratio1.44
Total debt/total equity0.0252
Total debt/total capital0.0246
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 50.00% and 62.66%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)0.32%
Div growth rate (5 year)--
Payout ratio (TTM)73.24%
EPS growth(5 years)24.29
EPS (TTM) vs
TTM 1 year ago
-46.39
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.